LEETRO
430425
Geovis Insighter Technology
920116
Beijing Global Safety Technology
300523
4
Zhejiang JW Precision Machinery
300984
5
Wintao Communications
301139
US Stock MarketDetailed Quotes
CMPS COMPASS Pathways
- 3.850
- +0.180+4.90%
Close Mar 4 16:00 ET
356.79MMarket Cap-1.67P/E (TTM)
3.900High3.560Low992.78KVolume3.600Open3.670Pre Close3.69MTurnover1.39%Turnover RatioLossP/E (Static)92.67MShares11.33052wk High2.31P/B275.56MFloat Cap3.16552wk Low--Dividend TTM71.57MShs Float61.690Historical High--Div YieldTTM9.28%Amplitude3.165Historical Low3.721Avg Price1Lot Size
Trending Stocks
Discussing
As China's 'two sessions' commence: How will Chinese stocks perform?
🎙️Discussion 1. With the government's emphasis on technological innovation and sustainability, which industry sectors do you believe hold t
Moomoo News Global
Mar 4 23:26
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
COMPASS Pathways Stock Forum
Can Compass Pathways' $140M Cash Infusion Offset Growing Losses in Psychedelic Treatment Race?
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, ...
https://www.fda.gov/news-events/press-announcements/fda-issues-first-draft-guidance-clinical-trials-psychedelic-drugs
NEWS
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
NEWS
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
• $Genco Shipping & Trading (GNK.US)$ +4.7% (positive Barrons article)
• $NextDecade (NEXT.US)$ +4.7% (files for 4618226 share common stock offering by selling shareholder)
• $COMPASS Pathways (CMPS.US)$ +4.7% (COMPASS Pathways presents largest ever study of psilocybin therapy at American Psychiatric Association annual meeting)
• $Canoo (GOEV.US)$ +3.5% (files for 48043111 share common stock offering by selling shareholder)
• $American Axle & Mfg (AXL.US)$ +3.7% (pr...
$Cybin (CYBN.US)$ $Enveric Biosciences (ENVB.US)$ $Mind Medicine (MNMD.US)$ $Seelos Therapeutics (SEEL.US)$ $COMPASS Pathways (CMPS.US)$ $ADVISORSHARES PSYCHEDELICS ETF (PSIL.US)$ building up short positions. The whole sector has taken a huge smack regardless of the fda approvels, Cybin having a clinic in New York. Envb having its Psy-ai. Seelos is up big without any indication of why. Mind med is down, started more studies on mdma and lsd. Get ready and load up. Things are looking strange.
No comment yet